BioMed Realty has announced that CordenPharma Colorado has signed a long-term lease for a new laboratory facility at Flatiron Park in Boulder, marking a significant expansion for the peptide drug manufacturing specialist and reinforcing the region’s position as a growing life sciences innovation hub.
Under the agreement, CordenPharma Colorado will occupy 64,000 square feet at the newly developed building located at 5505 Central within Flatiron Park. The 15-year lease highlights continued demand for specialized laboratory infrastructure designed for advanced scientific research and pharmaceutical manufacturing.
The facility represents Boulder’s first purpose-built speculative laboratory building and was developed to support high-performance research and development activities. Designed with modern life sciences operations in mind, the building includes robust power capacity, adaptable laboratory layouts, advanced mechanical and utility systems, and specialized waste disposal capabilities required for complex scientific processes.
According to BioMed Realty, the building has achieved LEED® Gold certification and was engineered to accommodate companies working in highly technical research fields. These features are particularly important for organizations engaged in pharmaceutical process development and advanced drug manufacturing, where stable infrastructure and specialized lab configurations are essential.
CordenPharma Colorado will serve as the sole tenant of the facility. The space will primarily house process development and analytical laboratories that support the production of peptide-based active pharmaceutical ingredients. By locating the new laboratories adjacent to its existing manufacturing facility, the company aims to streamline development activities and strengthen the integration between early-stage research and large-scale production.
The expansion will focus on peptide Active Pharmaceutical Ingredient (API) development, a growing segment of the pharmaceutical market. Peptide-based therapies are increasingly being used to treat a wide range of conditions, including metabolic disorders, oncology indications, and rare diseases. The new laboratories will support development programs from early research stages through commercial manufacturing.
Jon Bergschneider said the project reflects the company’s strategy of developing flexible infrastructure capable of supporting complex scientific operations. He noted that the new building was designed to provide sophisticated research users with both performance and adaptability while also offering a collaborative campus environment.
Flatiron Park has emerged as one of Boulder’s key innovation campuses, hosting organizations from life sciences, quantum technology, and advanced research sectors. BioMed Realty has invested heavily in the campus to create an integrated environment that includes resilient infrastructure, flexible building designs, and shared amenities aimed at supporting research-driven companies.
For CordenPharma, the new facility represents a major step in expanding its capabilities to meet increasing global demand for peptide drug development services. Michael Landau said the company expects the expansion to accelerate its strategic growth and enhance its ability to support pharmaceutical partners seeking specialized outsourcing services.
Landau also noted that the development will help create additional jobs and attract scientific talent to the Boulder region, strengthening the local life sciences ecosystem.
In addition to supporting operations in Colorado, the new laboratories will be integrated into CordenPharma’s global network of facilities across Europe and the United States, further enhancing the company’s ability to deliver peptide development and manufacturing services to clients worldwide.
Jennifer Chavez added that the lease agreement demonstrates BioMed Realty’s role in supporting innovation-focused companies by providing high-quality research infrastructure tailored to their operational needs.
With the addition of CordenPharma at 5505 Central, Flatiron Park continues to grow as a strategic center for life sciences development and advanced technology research in Boulder.